The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AMLX | +162.9% | N/A | N/A | -18% |
| S&P | +13% | +86.41% | +13.26% | +45% |
Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in the provision of disease-modifying solutions for neurodegenerative diseases. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.
A science-first biotech fund just sized up its stake in an ALS-focused company heading into a pivotal year for the firm.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | -100.0% |
| Gross Profit | -$0.12M | 80.5% |
| Gross Margin | -147.60% | 0.0% |
| Market Cap | $1.45B | 557.2% |
| Market Cap / Employee | $11.79M | 0.0% |
| Employees | 123 | -68.0% |
| Net Income | -$34.39M | 52.7% |
| EBITDA | -$35.91M | 8.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $225.18M | 213.4% |
| Accounts Receivable | $0.13M | -92.4% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $4.95M | 732.6% |
| Short Term Debt | $0.98M | -50.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -48.67% | 23.7% |
| Return On Invested Capital | -190.76% | -136.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$30.39M | 26.9% |
| Operating Free Cash Flow | -$30.37M | 26.9% |
| Metric | Q4 2023 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 20.88 | - | |||
| Price to Book | 1.32 | 1.47 | 2.83 | 7.22 | 755.04% |
| Price to Sales | 0.48 | 0.43 | 1.12 | 2.97 | 10.94% |
| Price to Tangible Book Value | 1.32 | 1.47 | 2.83 | 7.22 | 755.04% |
| Price to Free Cash Flow TTM | 95.39 | 12.48 | - | ||
| Enterprise Value to EBITDA | -2.09 | -2.67 | -9.28 | -25.91 | -9167.58% |
| Free Cash Flow Yield | 1.0% | 8.0% | - | ||
| Return on Equity | -100.9% | -83.2% | -87.4% | -56.5% | -33.05% |
| Total Debt | $1.98M | $1.38M | $5.96M | $5.94M | 131.20% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
